

Without Cirrhosis

TABLE 111: SVR GENOTYPE 1 WITHOUT CIRRHOSIS TREATMENT-EXPERIENCED WITH PRIOR RELAPSE: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|-----------------------------------|-------------------------------|--------------------------|-------------------------|
| SIM12 PR24-48 RGT | PR48 | 2.12 (1.64 to 2.57) | 41.14 (24.41 to 51.74) |
| B32 PR36-48 RGT | | 2.14 (1.46 to 2.75) | 41.82 (18.10 to 56.71) |
| PAR/RIT12 + OMB12 + DAS12 | | 2.61 (2.16 to 3.09) | 59.38 (45.37 to 66.21) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 2.56 (2.09 to 3.04) | 57.48 (42.59 to 64.71) |
| B32 PR36-48 RGT | SIM12 PR24-48 RGT | 1.01 (0.72 to 1.33) | 0.71 (–23.12 to 21.41) |
| PAR/RIT12 + OMB12 + DAS12 | | 1.23 (1.02 to 1.56) | 17.99 (1.79 to 34.54) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.20 (1.06 to 1.45) | 15.87 (5.08 to 28.67) |
| PAR/RIT12 + OMB12 + DAS12 | B32 PR36-48 RGT | 1.22 (0.99 to 1.68) | 17.12 (–0.53 to 39.29) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | | 1.19 (0.97 to 1.64) | 15.34 (–2.69 to 37.18) |
| PAR/RIT12 + OMB12 + DAS12 + RBV12 | PAR/RIT12 + OMB12 + DAS12 | 0.98 (0.83 to 1.14) | –1.93 (–16.13 to 11.93) |
| | | | |
| Random effect model | Residual deviance | 8.881 vs. 10 data points | |
| | Deviance information criteria | 59.882 | |
| Fixed effect model | Residual deviance | 8.843 vs. 10 data points | |
| | Deviance information criteria | 59.796 | |

B = boceprevir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.